Tuesday, May 25, 2021 Daily Archives

Early Selection of Optimal Clones Made Easy: A New, High-Throughput, All-in-One Solution for Mannose Glycans Screening and Assessment of Critical Quality Attributes

by

Glycosylation is a critical quality attribute (CQA) and imparts properties such as stability, folding, solubility, cell-cell interaction and adhesion to proteins. Antibody glycosylation for example is critical due to the role carbohydrates play in modulating effector functions which affect safety and efficacy of therapeutic antibodies. The NEW Octet® GlyM Kit is designed to provide cell line development and upstream bioprocessing Octet® users with a ready to use kit for the rapid screening of % mannose content of purified and cell…

May 25, 2021

Biogen partners with Gingko to develop gene therapy platform

by

Biogen will use Gingko Bioworks’ mammalian cell programming platform to help advance its AAV-based vector manufacturing. Under the terms of the agreement, Gingko will provide Biogen with access to its cell programming capabilities and platform. Gingko will use its bioengineering resources and biomanufacturing space to enhance Biogen’s AAV production titers in its gene therapy manufacturing processes. Biogen will pay $5 million upfront, but Gingko has the potential to receive $115 million depending on research, development, and commercial milestones. Biogen says…

May 25, 2021

Gamma adds transfection reagents for RNA and gene therapy delivery in Mirus deal

by

Gamma Biosciences has acquired a controlling stake in lipid-polymer nanocomplex (LPNC) developer Mirus Bio, bolstering its cell line development, viral vector manufacturing, and cell engineering offerings. Investment firm KKR launched Gamma Biosciences last year to operate a portfolio of life sciences tools investments and acquisitions. The latest deal has seen Gamma take a controlling stake in Madison, Wisconsin-headquartered Mirus, a supplier of transfection reagents used to support gene therapy and messenger RNA vaccine production. Financial terms have not been divulged.…

May 25, 2021